CY2016012I1 - Ετεροκυκλικη ενωση χρησιμη ως διαμορφωτης μεταφορεων κασετας συνδεσης με ατρ - Google Patents

Ετεροκυκλικη ενωση χρησιμη ως διαμορφωτης μεταφορεων κασετας συνδεσης με ατρ

Info

Publication number: CY2016012I1
Authority: CY; Cyprus
Prior art keywords: atp; compound used; heterocyclic compound; cassette transport; transport modulator
Prior art date: 2005-11-08

Application number

CY2016012C

Other languages

English (en)

Other versions

CY2016012I2 (el

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-08

Filing date

2016-05-17

Publication date

2016-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37766297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2016012(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-05-17 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2016-10-05 Publication of CY2016012I1 publication Critical patent/CY2016012I1/el

2016-10-05 Publication of CY2016012I2 publication Critical patent/CY2016012I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)

CY2016012C 2005-11-08 2016-05-17 Ετεροκυκλικη ενωση χρησιμη ως διαμορφωτης μεταφορεων κασετας συνδεσης με ατρ CY2016012I2 (el)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US73450605P	2005-11-08	2005-11-08
US75408605P	2005-12-27	2005-12-27
US80245806P	2006-05-22	2006-05-22
EP06837028.7A EP1945632B1 (en)	2005-11-08	2006-11-08	Heterocyclic modulators of atp-binding cassette transporters

Publications (2)

Publication Number	Publication Date
CY2016012I1 true CY2016012I1 (el)	2016-10-05
CY2016012I2 CY2016012I2 (el)	2016-10-05

Family

ID=37766297

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20141100743T CY1115750T1 (el)	2005-11-08	2014-09-15	Φαρμακευτικη συνθεση η οποια περιεχει ενα ετεροκυκλικο διαμορφωτη μεταφορεων κασετας συνδεσης με ατρ
CY2016012C CY2016012I2 (el)	2005-11-08	2016-05-17	Ετεροκυκλικη ενωση χρησιμη ως διαμορφωτης μεταφορεων κασετας συνδεσης με ατρ
CY20171100364T CY1118768T1 (el)	2005-11-08	2017-03-22	Ετεροκυκλικοι ρυθμιστες μεταφορεων κασετας συνδεσης atp

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20141100743T CY1115750T1 (el)	2005-11-08	2014-09-15	Φαρμακευτικη συνθεση η οποια περιεχει ενα ετεροκυκλικο διαμορφωτη μεταφορεων κασετας συνδεσης με ατρ

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20171100364T CY1118768T1 (el)	2005-11-08	2017-03-22	Ετεροκυκλικοι ρυθμιστες μεταφορεων κασετας συνδεσης atp

Country Status (24)

Country	Link
US (18)	US7741321B2 (el)
EP (6)	EP3696174A1 (el)
JP (4)	JP5317184B2 (el)
KR (6)	KR20130042034A (el)
CN (2)	CN102775396B (el)
AU (1)	AU2006311650B2 (el)
CA (1)	CA2627358C (el)
CY (3)	CY1115750T1 (el)
DK (4)	DK1945632T3 (el)
ES (5)	ES2778846T3 (el)
HK (2)	HK1125366A1 (el)
HU (2)	HUE032640T2 (el)
IL (2)	IL191141A (el)
LT (2)	LT2774925T (el)
LU (1)	LU93073I2 (el)
NL (1)	NL300812I2 (el)
NO (1)	NO20082674L (el)
NZ (1)	NZ567892A (el)
PL (4)	PL2395002T3 (el)
PT (4)	PT2404919E (el)
RU (3)	RU2463303C3 (el)
SI (4)	SI2395002T1 (el)
WO (1)	WO2007056341A1 (el)
ZA (1)	ZA200803887B (el)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
CN1898221A (zh)	2003-09-06	2007-01-17	沃泰克斯药物股份有限公司	Atp－结合弹夹转运蛋白的调控剂
JP4869072B2 (ja) *	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
FR2864083B1 (fr) *	2003-12-18	2007-04-13	Galderma Res & Dev	Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation.
US8759335B2 (en) *	2004-01-30	2014-06-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
AU2005258320B2 (en)	2004-06-24	2010-09-16	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
NZ590359A (en)	2005-01-25	2012-08-31	Synta Pharmaceuticals Corp	Pyrazine compounds for inflammation and immune-related uses
JP5143738B2 (ja)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節物質
ES2778846T3 (es)	2005-11-08	2020-08-12	Vertex Pharma	Moduladores heterocíclicos de transportadores de casete de unión a ATP
US20120232059A1 (en) *	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
HUE049976T2 (hu)	2005-12-28	2020-11-30	Vertex Pharma	N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
JP5165586B2 (ja) *	2005-12-28	2013-03-21	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
SI3091011T1 (en) *	2006-04-07	2018-06-29	Vertex Pharmaceuticals Incorporated	Modulators of ATP conveyor belt conveyors
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
KR20100007956A (ko)	2007-05-03	2010-01-22	화이자 리미티드	나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
WO2008141119A2 (en)	2007-05-09	2008-11-20	Vertex Pharmaceuticals Incorporated	Modulators of cftr
AU2013231028B2 (en) *	2007-05-09	2016-05-26	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2008147797A2 (en) *	2007-05-25	2008-12-04	Vertex Pharmaceuticals Incorporated	Ion channel modulators and methods of use
CN101827593B (zh)	2007-08-24	2013-07-24	沃泰克斯药物股份有限公司	用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
EP2578571B1 (en)	2007-11-16	2015-09-16	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-binding cassette transporters
AU2013231151B2 (en) *	2007-11-16	2015-06-25	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-Binding Cassette transporters
EP2222638A2 (en) *	2007-11-21	2010-09-01	Decode Genetics EHF	Biaryl pde4 inhibitors for treating inflammation
AU2013231109B2 (en) *	2007-12-07	2015-10-29	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
LT3170818T (lt)	2007-12-07	2020-05-25	Vertex Pharmaceuticals Incorporated	Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
AU2016204422B2 (en) *	2007-12-07	2017-11-16	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
AU2013205160B2 (en) *	2007-12-07	2016-05-19	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
ES2625957T3 (es) *	2007-12-07	2017-07-21	Vertex Pharmaceuticals Incorporated	Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
AU2016200431B2 (en) *	2007-12-07	2017-08-24	Vertex Pharmaceuticals Incorporated	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
MX2010006238A (es) *	2007-12-07	2010-08-11	Vertex Pharma	Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
AU2013205162B2 (en) *	2008-02-28	2015-07-09	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as CFTR modulators
AU2015228930B2 (en) *	2008-02-28	2017-02-23	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as CFTR modulators
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
AU2013270464B2 (en) *	2008-03-31	2016-05-26	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as CFTR modulators
NZ616097A (en)	2008-03-31	2015-04-24	Vertex Pharma	Pyridyl derivatives as cftr modulators
EP3578195B1 (en)	2008-06-26	2023-08-09	Zevra Denmark A/S	Use of hsp70 as a regulator of enzymatic activity
WO2010011302A1 (en) *	2008-07-22	2010-01-28	Chdi, Inc.	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US8853424B2 (en)	2008-08-11	2014-10-07	Japan Science And Technology Agency	Protein cross-linking inhibitor
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
GB0817207D0 (en)	2008-09-19	2008-10-29	Pimco 2664 Ltd	therapeutic apsac compounds and their use
KR20110063578A (ko) *	2008-09-29	2011-06-10	버텍스 파마슈티칼스 인코포레이티드	3－（6－（1－（2,2－디플루오로벤조［ｄ］［1,3］디옥솔－5－일）사이클로프로판카복스아미도）－3－메틸피리딘－2－일）벤조산의 투여 단위
ES2483690T3 (es)	2008-10-23	2014-08-07	Vertex Pharmaceuticals Incorporated	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US8513242B2 (en)	2008-12-12	2013-08-20	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
KR101955863B1 (ko)	2009-03-20	2019-03-07	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
CN102665715A (zh)	2009-10-22	2012-09-12	沃泰克斯药物股份有限公司	治疗囊性纤维化和其他慢性疾病的组合物
US20130004477A1 (en) *	2009-10-26	2013-01-03	Zhe Lu	Methods for Treating Inflammation and Oxidative Stress Related Diseases
EP2519515B1 (en) *	2009-12-31	2013-11-06	Novartis AG	Pyrazine derivatives and their use in the treatment of neurological disorders
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SI3150198T1 (sl)	2010-04-07	2021-11-30	Vertex Pharmaceuticals Incorporated	Farmacevtski sestavki 3-(6-(1-(2,2-difluorobenzo(D)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline in dajanje le-teh
TWI549950B (zh)	2010-04-07	2016-09-21	維泰克斯製藥公司	３－（６－（１－（２，２－二氟苯并［ｄ］［１，３］二氧雜環戊烯－５－基）環丙烷甲醯胺基）－３－甲基吡啶－２－基）苯甲酸之固體形式
EP3138563A1 (en)	2010-04-22	2017-03-08	Vertex Pharmaceuticals Inc.	Pharmaceutical compositions and administrations thereof
NZ603044A (en)	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
KR20130056244A (ko)	2010-04-22	2013-05-29	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
NZ603043A (en) *	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
US9133123B2 (en)	2010-04-23	2015-09-15	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AU2011248579A1 (en)	2010-04-27	2012-11-29	Calcimedica, Inc.	Compounds that modulate intracellular calcium
AU2011248877B9 (en)	2010-04-27	2015-11-05	Calcimedica Inc.	Compounds that modulate intracellular calcium
US10703722B2 (en)	2010-04-27	2020-07-07	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en)	2010-06-14	2012-12-18	Cystic Fibrosis Foundation Therapeutics, Inc.	Pyrimidine compounds and methods of making and using same
US9079891B2 (en)	2010-08-27	2015-07-14	Calcimedica, Inc.	Compounds that modulate intracellular calcium
BR112013013143A2 (pt)	2010-11-30	2016-08-23	Orphazyme Aps	composto, e, método de tratamento de uma doença de armazenagem lisossômica
CN102133402B (zh) *	2011-03-24	2013-06-12	首都医科大学附属北京同仁医院	囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
WO2012170931A2 (en)	2011-06-10	2012-12-13	Calcimedica, Inc.	Compounds that modulate intracellular calcium
PH12017502049A1 (en)	2011-08-30	2018-08-29	Chdi Foundation Inc	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
KR20140072037A (ko)	2011-08-30	2014-06-12	씨에이치디아이 파운데이션, 인코포레이티드	키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
WO2013059677A1 (en)	2011-10-19	2013-04-25	Calcimedica, Inc.	Compounds that modulate intracellular calcium
AU2012335714B2 (en)	2011-11-08	2017-04-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
TWI640519B (zh) *	2011-11-29	2018-11-11	泰緯生命科技股份有限公司	Ｈｅｃ１活性調控因子及其調節方法
ME03464B (me)	2012-01-25	2020-01-20	Vertex Pharma	Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
AU2013226076B2 (en)	2012-02-27	2017-11-16	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2885301A1 (de)	2012-08-17	2015-06-24	Bayer CropScience AG	Azaindolcarbonsäure- und -thiocarbonsäureamide als insektizide und akarizide
RS57831B2 (sr)	2012-11-02	2024-02-29	Vertex Pharma	Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr
ITMI20122065A1 (it)	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2014141064A1 (en)	2013-03-13	2014-09-18	Novartis Ag	Notch2 binding molecules for treating respiratory diseases
EP2968285A4 (en) *	2013-03-13	2016-12-21	Flatley Discovery Lab	COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
MX365950B (es)	2013-03-13	2019-06-19	Flatley Discovery Lab Llc	Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
WO2014186704A2 (en) *	2013-05-17	2014-11-20	N30 Pharmaceuticals, Inc.	Novel compounds for the treatment of cystic fibrosis
GB201311361D0 (en)	2013-06-26	2013-08-14	Pimco 2664 Ltd	Compounds and their therapeutic use
RS61790B1 (sr)	2013-11-12	2021-06-30	Vertex Pharma	Proces pripreme farmaceutskih sastava za lečenje bolesti na koje utiče cftr
CN103664796A (zh) *	2013-12-06	2014-03-26	辽宁师范大学	5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法
WO2015143376A1 (en) *	2014-03-21	2015-09-24	Nivalis Therapeutics, Inc.	Novel compounds for the treatment of cystic fibrosis
HUE039062T2 (hu)	2014-04-15	2018-12-28	Vertex Pharma	Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
EP2932966A1 (en)	2014-04-16	2015-10-21	Novartis AG	Gamma secretase inhibitors for treating respiratory diseases
WO2016011316A1 (en)	2014-07-17	2016-01-21	Chdi Foundation, Inc.	Methods and compositions for treating hiv-related disorders
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
HUE054957T2 (hu)	2014-09-15	2021-10-28	Orphazyme As	Arimoklomol készítése
SMT202000540T1 (it)	2014-10-06	2020-11-10	Vertex Pharma	Modulatori di regolatore di conduttanza transmembrana di fibrosi cistica
AU2015330923B2 (en)	2014-10-07	2020-03-12	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016058544A1 (en) *	2014-10-16	2016-04-21	Syros Pharmaceuticals, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
RS61267B1 (sr)	2014-10-31	2021-01-29	Abbvie Overseas Sarl	Supstituisani hromani i postupci za upotrebu
WO2016081556A1 (en)	2014-11-18	2016-05-26	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
SI3262028T1 (sl)	2014-12-17	2022-02-28	Pimco 2664 Limited	N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba
EA202091639A3 (ru)	2015-02-27	2021-06-30	Кальцимедика, Инк.	Лечение панкреатита
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
FR3035105A1 (fr) *	2015-04-16	2016-10-21	Metabrain Res	Derives utiles dans le traitement de l'atrophie musculaire
SI3319959T1 (sl)	2015-07-06	2022-02-28	Alkermes, Inc.	Hetero-halo inhibitorji histonske deacetilaze
WO2017007755A1 (en)	2015-07-06	2017-01-12	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
JP6738575B2 (ja)	2015-08-07	2020-08-12	カルシメディカ，インク．	脳卒中および外傷性脳損傷の処置のためのｃｒａｃチャネル阻害剤の使用
CN106432209A (zh) *	2015-08-11	2017-02-22	苏州晶云药物科技有限公司	Lumacaftor的新晶型及其制备方法
WO2017056109A2 (en) *	2015-09-29	2017-04-06	Mylan Laboratories Limited	Novel forms of lumacaftor and processes for the preparation thereof
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
JP6854817B2 (ja)	2015-11-06	2021-04-07	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｐｉ３ｋ−ガンマ阻害薬としての複素環式化合物
WO2017118915A1 (en) *	2016-01-04	2017-07-13	Dr. Reddy's Laboratories Limited	Amorphous and crystalline solid forms of lumacaftor or its complex and preparative processes thereof
ES2833955T3 (es)	2016-01-05	2021-06-16	Incyte Corp	Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
CN107033120B (zh) *	2016-02-03	2020-03-17	苏州旺山旺水生物医药有限公司	2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法
WO2017137900A1 (en)	2016-02-10	2017-08-17	Lupin Limited	Amorphous lumacaftor and its solid dispersion
EP3418276A4 (en) *	2016-02-15	2019-07-31	Taisho Pharmaceutical Co., Ltd.	AZOL SUBSTITUTED PYRIDINE COMPOUND
WO2017175161A1 (en) *	2016-04-07	2017-10-12	Dr. Reddy’S Laboratories Limited	Solid forms of lumacaftor, its salts and processes thereof
US10898476B2 (en)	2016-04-13	2021-01-26	Orphazyme A/S	Heat shock proteins and cholesterol homeostasis
KR101683011B1 (ko)	2016-04-20	2016-12-07	에스텍전자 주식회사	플렉시블 필름히터를 적용한 온수모듈장치 및 이를 구비하는 온수매트
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
CA3021900A1 (en)	2016-04-29	2017-11-02	Orphazyme A/S	Arimoclomol for treating glucocerebrosidase associated disorders
TW201803871A (zh)	2016-06-24	2018-02-01	英塞特公司	作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
MX2021013639A (es) *	2016-12-09	2022-09-30	Vertex Pharma	Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
EP3565814B1 (en)	2017-01-09	2024-07-10	Laurus Labs Limited	Process and crystalline forms of lumacaftor
SI3570834T1 (sl)	2017-01-11	2022-05-31	Alkermes, Inc.	Biciklični inhibitorji histonske deacetilaze
CN108658851B (zh) *	2017-03-27	2023-06-06	山东特珐曼药业有限公司	2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
AU2018313094A1 (en)	2017-08-07	2020-02-20	Rodin Therapeutics, Inc.	Bicyclic inhibitors of histone deacetylase
CA3020592A1 (en)	2017-10-17	2019-04-17	Apotex Inc.	Novel crystalline form of lumacaftor
US20190210973A1 (en)	2018-01-05	2019-07-11	The Curators Of The University Of Missouri	Compounds and methods for treatment of cystic fibrosis
US11793884B2 (en)	2018-01-29	2023-10-24	Ohio State Innovation Foundation	Cyclic peptidyl inhibitors of CAL-PDZ binding domain
CN110950807B (zh) *	2018-09-26	2023-03-03	中国科学院上海药物研究所	联芳基类化合物、其制备方法、药物组合物及其应用
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
US11465982B2 (en) *	2019-07-22	2022-10-11	Boehringer Ingelheim International Gmbh	Pyridazines
BR112022002605A2 (pt)	2019-08-14	2022-05-03	Vertex Pharma	Formas cristalinas de moduladores de cftr
JP2022545359A (ja)	2019-08-14	2022-10-27	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子モジュレーター
WO2021030555A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3970718A1 (en)	2020-09-18	2022-03-23	Charité - Universitätsmedizin Berlin	New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators
US20230373939A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
JP2023545081A (ja)	2020-10-07	2023-10-26	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子モジュレーター
CN116670143A (zh)	2020-10-07	2023-08-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
WO2022076620A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076629A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20230198A (es)	2020-10-07	2023-07-03	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230365587A1 (en)	2020-10-07	2023-11-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4247792A1 (en)	2020-11-19	2023-09-27	Zevra Denmark A/S	Processes for preparing arimoclomol citrate and intermediates thereof
IL314691A (en)	2022-02-03	2024-10-01	Vertex Pharma	PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
KR20240144973A (ko)	2022-02-03	2024-10-04	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 치료 방법
EP4476230A1 (en)	2022-02-08	2024-12-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20240457A (es)	2022-04-06	2024-12-11	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AU2023273614A1 (en)	2022-05-16	2024-11-07	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2023224924A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
TW202421102A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
WO2024072793A1 (en) *	2022-09-26	2024-04-04	Rectify Pharmaceuticals, Inc.	Pyridine carboxamide compounds and their use in treating medical conditions
WO2024072794A1 (en) *	2022-09-26	2024-04-04	Rectify Pharmaceuticals, Inc.	Pyridine carboxamide compounds and their use in treating medical conditions

Family Cites Families (260)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758475A (en)	1971-07-20	1973-09-11	Sandoz Ag	Pyrido(2,3-d)pyrimidin 2 ones
EP0081756B1 (en)	1981-12-14	1985-05-15	MEDEA RESEARCH S.r.l.	New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
IT1226048B (it) *	1981-12-14	1990-12-10	Medea Res Srl	Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
US4501729A (en)	1982-12-13	1985-02-26	Research Corporation	Aerosolized amiloride treatment of retained pulmonary secretions
EP0278374A3 (de)	1987-02-06	1989-03-01	Pharmatest Apparatebau Gmbh	Vorrichtung zur Bestimmung der Wirkstoff-Freigabe von pharmazeutischen Produkten
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5981714A (en)	1990-03-05	1999-11-09	Genzyme Corporation	Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja)	1990-11-27	2001-05-21	武田薬品工業株式会社	ピリドピリダジン誘導体およびその用途
US5612360A (en)	1992-06-03	1997-03-18	Eli Lilly And Company	Angiotensin II antagonists
CA2107196A1 (en)	1992-09-29	1994-03-30	Mitsubishi Chemical Corporation	Carboxamide derivatives
US6060024A (en)	1993-07-14	2000-05-09	Zymark Corporation	Automatic dissolution testing system
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
GB9317764D0 (en)	1993-08-26	1993-10-13	Pfizer Ltd	Therapeutic compound
RU2136661C1 (ru)	1993-10-21	1999-09-10	Джи Ди Сирл энд Ко.	Амидинопроизводные, их применение и фармацевтическая композиция
DE4405712A1 (de)	1994-02-23	1995-08-24	Basf Ag	Substituierte Naphthyridine und deren Verwendung
NO305987B1 (no)	1994-04-11	1999-08-30	Sankyo Co	Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
EP0784620B1 (en)	1994-09-27	1999-12-08	Janssen Pharmaceutica N.V.	N-substituted piperidinyl bicyclic benzoate derivatives
AU2788695A (en)	1994-10-28	1996-05-23	Neurosearch A/S	Patch clamp apparatus and technique having high throughput and low fluid volume requirements
US5656256A (en)	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en)	1994-12-19	1996-04-23	Warner-Lambert Company	Sulfonate ACAT inhibitors
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
CA2249615A1 (en)	1996-04-03	1997-10-09	Robert Gomez	Inhibitors of farnesyl-protein transferase
DE69713402T2 (de)	1996-08-23	2002-11-07	Agouron Pharma	Liganden des neuropeptids y
EP1003374A1 (en)	1996-12-30	2000-05-31	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
CO4920215A1 (es)	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5948814A (en)	1997-02-20	1999-09-07	The Curators Of The University Of Missouri	Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en)	1997-04-18	1998-10-29	Smithkline Beecham Plc	Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
HUP0003881A3 (en)	1997-10-02	2001-04-28	Sankyo Co	Amidocarboxylic acid derivatives
DK1054996T3 (da)	1998-02-17	2004-05-24	Searle & Co	Fremgangsmåde til den enzymatiske adskillelse af lactamer
ES2188264T3 (es)	1998-06-08	2003-06-16	Schering Corp	Antagonistas del receptor del neuropeptido y5.
US6426331B1 (en) *	1998-07-08	2002-07-30	Tularik Inc.	Inhibitors of STAT function
AUPP609198A0 (en)	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
EP1161240B1 (en)	1998-12-18	2005-08-17	Bristol-Myers Squibb Pharma Company	N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE496032T1 (de) *	1999-02-24	2011-02-15	Hoffmann La Roche	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
HUP0200124A3 (en)	1999-02-24	2004-03-01	Hoffmann La Roche	Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them
NZ513370A (en)	1999-02-24	2004-02-27	F	3-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US7407978B2 (en) *	1999-04-06	2008-08-05	Theracos, Inc.	Heterocyclic analogs of diphenylethylene compounds
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU6687900A (en)	1999-06-18	2001-01-09	Bayer Aktiengesellschaft	Phenoxy fluoropyrimidines
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en)	1999-12-16	2001-06-28	Novartis Ag	N-heteroaryl-amides and their use as parasiticides
JP2003519698A (ja)	2000-01-07	2003-06-24	トランスフォームファーマスーティカルズ，インコーポレイテッド	多様な固体形態のハイスループットでの形成、同定および分析
AU2001233069A1 (en)	2000-01-28	2001-08-07	Biogen, Inc.	Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en)	2000-02-01	2001-08-09	Cor Therapeutics, Inc.	Inhibitors of factor xa
AU2001249417A1 (en)	2000-04-26	2001-11-07	Gliatech, Inc.	Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2001083517A1 (en)	2000-05-03	2001-11-08	Tularik Inc.	Stat4 and stat6 binding dipeptide derivatives
US6499984B1 (en)	2000-05-22	2002-12-31	Warner-Lambert Company	Continuous production of pharmaceutical granulation
CA2379445C (en)	2000-06-01	2007-08-21	Bristol-Myers Squibb Pharma Company	Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production
TWI259180B (en) *	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
KR100896664B1 (ko)	2000-09-15	2009-05-14	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
JP4272338B2 (ja)	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
WO2002028348A2 (en)	2000-10-04	2002-04-11	The Children's Hospital Of Philadelphia	Compositions and methods for treatment of cystic fibrosis
GB2367816A (en)	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
ATE269856T1 (de)	2000-10-20	2004-07-15	Merck Patent Gmbh	Chirale binaphtol-verbindungen
US6884782B2 (en)	2000-11-08	2005-04-26	Amgen Inc.	STAT modulators
EP1339402B1 (en)	2000-12-01	2010-08-25	Eisai Inc.	Azaphenanthridone derivatives and their use as parp inhibitors
GB0102687D0 (en)	2001-02-02	2001-03-21	Pharmacia & Upjohn Spa	Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US20100074949A1 (en) *	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
US6962674B2 (en)	2001-02-28	2005-11-08	Varian, Inc.	Dissolution test apparatus
JP2005520171A (ja) *	2001-04-10	2005-07-07	トランス　テック　ファーマ，インコーポレイテッド	ドラッグディスカバリーに関する、プローブ、システム、および方法
PT1385577E (pt)	2001-04-23	2006-08-31	Hoffmann La Roche	Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna
WO2002096421A1 (en)	2001-05-22	2002-12-05	Neurogen Corporation	5-substituted-2-arylpyridines as crf1 modulators
US20030083345A1 (en)	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en)	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
WO2003007888A2 (en)	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
JP4558314B2 (ja)	2001-07-20	2010-10-06	ベーリンガーインゲルハイム（カナダ）リミテッド	ウイルスポリメラーゼインヒビター
AU2002333524A1 (en)	2001-09-11	2003-03-24	Glaxosmithkline K.K.	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja)	2001-11-19	2003-05-27	Toray Ind Inc	環状含窒素誘導体
JP2003221386A (ja)	2001-11-26	2003-08-05	Takeda Chem Ind Ltd	二環性誘導体、その製造法およびその用途
US20030171411A1 (en)	2001-12-21	2003-09-11	Kodra Janos Tibor	Amide derivatives as therapeutic agents
TW200307539A (en)	2002-02-01	2003-12-16	Bristol Myers Squibb Co	Cycloalkyl inhibitors of potassium channel function
TW200304820A (en)	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr)	2002-06-12	2005-03-11		Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
WO2004014844A2 (en)	2002-08-09	2004-02-19	Transtech Pharma, Inc.	Aryl and heteroaryl compounds and methods to modulate coagulation
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
CA2501547A1 (en)	2002-10-15	2004-04-29	Rigel Pharmaceuticals, Inc.	Substituted indoles and their use as hcv inhibitors
CA2503713A1 (en)	2002-10-30	2004-05-21	Merck & Co., Inc.	Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
AU2003287449A1 (en)	2002-10-31	2004-05-25	Nanostream, Inc.	Parallel detection chromatography systems
AU2003288182A1 (en)	2002-11-26	2004-06-18	Universiteit Gent	Process and apparatus for continuous wet granulation of power material
BR0317183A (pt)	2002-12-12	2005-11-01	Pharmacia Corp	Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
PT1585739E (pt)	2003-01-06	2011-05-13	Lilly Co Eli	Arilciclopropilacetamidas substitu?das como activadores da glucocinase
CA2515669A1 (en)	2003-02-10	2004-08-26	Vertex Pharmaceuticals Incorporated	Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
US7223788B2 (en)	2003-02-14	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
AU2004236173B2 (en)	2003-04-30	2008-07-03	The Institutes For Pharmaceutical Discovery, Llc	Substituted carboxylic acids
EP1646615B1 (en) *	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
GB0315111D0 (en)	2003-06-27	2003-07-30	Cancer Rec Tech Ltd	Substituted 5-membered ring compounds and their use
US7893094B2 (en) *	2003-06-27	2011-02-22	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Amphiphilic pyridinium compounds, method of making and use thereof
JP2005053902A (ja)	2003-07-18	2005-03-03	Nippon Nohyaku Co Ltd	フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
US20050113379A1 (en)	2003-09-05	2005-05-26	Ping Ge	Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
CN1898221A (zh)	2003-09-06	2007-01-17	沃泰克斯药物股份有限公司	Atp－结合弹夹转运蛋白的调控剂
KR100528925B1 (ko) *	2003-09-09	2005-11-15	삼성에스디아이 주식회사	방열시트 및 이를 구비한 플라즈마 디스플레이 장치
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20050070718A1 (en) *	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
NZ546365A (en)	2003-10-08	2010-01-29	Vertex Pharma	Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups
EP1679069A4 (en)	2003-10-21	2009-05-13	Dainippon Sumitomo Pharma Co	NEW PIPERIDINE DERIVATIVE
FR2861304B1 (fr)	2003-10-23	2008-07-18	Univ Grenoble 1	Modulateurs des canaux cftr
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
JP4869072B2 (ja) *	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
US20070142411A1 (en)	2003-11-19	2007-06-21	James Hagan	Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
JP3746062B2 (ja)	2003-12-05	2006-02-15	第一製薬株式会社	固形製剤およびその製造方法
ES2238001B1 (es)	2004-01-21	2006-11-01	Vita Cientifica, S.L.	Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos.
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
WO2005074535A2 (en) *	2004-01-30	2005-08-18	Eisai Co., Ltd.	Cholinesterase inhibitors for spinal cord disorders
US8759335B2 (en)	2004-01-30	2014-06-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
JPWO2005080348A1 (ja)	2004-02-19	2007-08-02	萬有製薬株式会社	新規スルホンアミド誘導体
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
WO2005115399A2 (en)	2004-04-16	2005-12-08	Neurogen Corporation	Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
US7585885B2 (en)	2004-04-22	2009-09-08	Eli Lilly And Company	Pyrrolidine derivatives useful as BACE inhibitors
EP1740573A1 (en)	2004-04-22	2007-01-10	Eli Lilly And Company	Amides as bace inhibitors
EP1766062A4 (en)	2004-06-01	2008-07-09	Tm Bioscience Corp	METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS
TWI356036B (en)	2004-06-09	2012-01-11	Smithkline Beecham Corp	Apparatus and method for pharmaceutical production
AU2005258320B2 (en)	2004-06-24	2010-09-16	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US20140343098A1 (en)	2004-06-24	2014-11-20	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US8354427B2 (en) *	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
CA2572549A1 (en)	2004-07-01	2006-01-12	Warner-Lambert Company Llc	Preparation of pharmaceutical compositions containing nanoparticles
EP1771158A4 (en)	2004-07-02	2008-03-12	Advancis Pharmaceutical Corp	TABLET FOR PULSE DISTRIBUTION
CN1993339B (zh)	2004-08-06	2013-05-22	大塚制药株式会社	芳香化合物
US20060069110A1 (en)	2004-09-27	2006-03-30	Andersen Denise L	Substituted heterocyclic compounds and methods of use
CN101072758B (zh)	2004-10-12	2013-07-31	阿斯利康(瑞典)有限公司	喹唑啉衍生物
JP5036126B2 (ja)	2004-10-19	2012-09-26	日医工株式会社	エバスチン経口投与用製剤
WO2006051394A1 (en)	2004-11-15	2006-05-18	Pfizer Products Inc.	Azabenzoxazoles for the treatment of cns disorders
KR101291483B1 (ko)	2004-12-15	2013-07-30	돔페 파르마 에스.피.에이.	2-아릴프로피온산 유도체 및 이들을 함유하는 제약학적조성물
JP4790260B2 (ja)	2004-12-22	2011-10-12	出光興産株式会社	アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
WO2006080884A1 (en)	2005-01-27	2006-08-03	Astrazeneca Ab	Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7888374B2 (en)	2005-01-28	2011-02-15	Abbott Laboratories	Inhibitors of c-jun N-terminal kinases
US20090048258A1 (en)	2005-02-01	2009-02-19	Masaki Ogino	Amide Compound
WO2006099256A2 (en) *	2005-03-11	2006-09-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7297700B2 (en) *	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TWI377206B (en)	2005-04-06	2012-11-21	Theravance Inc	Crystalline form of a quinolinone-carboxamide compound
EP1710246A1 (en)	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
TW200716594A (en)	2005-04-18	2007-05-01	Neurogen Corp	Substituted heteroaryl CB1 antagonists
US20090215780A1 (en)	2005-04-19	2009-08-27	Bayer Pharmaceuticals Corporation	Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity
JP2008538561A (ja)	2005-04-20	2008-10-30	メルクエンドカムパニーインコーポレーテッド	アンジオテンシンｉｉ受容体アンタゴニスト
WO2006116218A1 (en)	2005-04-22	2006-11-02	Wyeth	Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
AU2006251624A1 (en)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
WO2006130403A1 (en)	2005-06-02	2006-12-07	Bayer Cropscience Ag	Phenylalkyl substituted heteroaryl devivatives
EP1919875A2 (en)	2005-06-21	2008-05-14	Astex Therapeutics Limited	Pyrazole derivatives and their use as pka and pkb modulators
US7316624B2 (en) *	2005-07-29	2008-01-08	Karsten Manufacturing Corporation	Golf club head for a hybrid golf club
JP5143738B2 (ja)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節物質
CN101287732A (zh)	2005-08-11	2008-10-15	沃泰克斯药物股份有限公司	囊性纤维化跨膜电导调节剂的调控剂
KR101292348B1 (ko)	2005-09-09	2013-09-09	네르 쎄라퓨틱스 리미티드	피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
ATE453384T1 (de)	2005-09-23	2010-01-15	Hoffmann La Roche	Neue dosierformulierung
JP2009511494A (ja)	2005-10-06	2009-03-19	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーター
PE20070528A1 (es)	2005-10-19	2007-07-20	Gruenenthal Chemie	Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
WO2007054480A1 (en)	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20120232059A1 (en)	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
ES2778846T3 (es) *	2005-11-08	2020-08-12	Vertex Pharma	Moduladores heterocíclicos de transportadores de casete de unión a ATP
ES2421450T3 (es)	2005-12-05	2013-09-02	Glaxosmithkline Llc	2-Pirimidinil-pirazolopiridinas inhibidoras de la quinasa ErbB
CA2634113A1 (en)	2005-12-24	2007-07-05	Vertex Pharmaceuticals Incorporated	Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007075946A1 (en)	2005-12-27	2007-07-05	Vertex Pharmaceuticals Incorporated	Compounds useful in cftr assays and methods therewith
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
JP5165586B2 (ja)	2005-12-28	2013-03-21	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物
HUE049976T2 (hu) *	2005-12-28	2020-11-30	Vertex Pharma	N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
WO2007079257A2 (en)	2005-12-30	2007-07-12	Caliper Life Sciences, Inc.	Integrated dissolution processing and sample transfer system
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
SI3091011T1 (en)	2006-04-07	2018-06-29	Vertex Pharmaceuticals Incorporated	Modulators of ATP conveyor belt conveyors
US10022352B2 (en) *	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
ES2377840T3 (es)	2006-05-12	2012-04-02	Vertex Pharmaceuticals, Inc.	Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
ES2471890T3 (es)	2006-11-03	2014-06-27	Vertex Pharmaceuticals Inc.	Derivados de azaindol como moduladores de CFTR
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en) *	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP5318400B2 (ja)	2006-11-20	2013-10-16	第一三共株式会社	レボフロキサシン含有錠剤
WO2008065068A2 (en)	2006-11-27	2008-06-05	Novartis Ag	Substituted dihydroimidazoles and their use in the treatment of tumors
CN101206205B (zh)	2006-12-22	2011-08-10	中国科学院大连化学物理研究所	微流量液相色谱在线大体积进样的方法和专用装置
CN101209399B (zh)	2006-12-27	2010-07-28	中国科学院沈阳应用生态研究所	一种往复式振荡机样品安放与固定装置
CN101210906A (zh)	2006-12-29	2008-07-02	电子科技大学	高通量自动化药物筛选实验检测系统
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
WO2008137787A2 (en)	2007-05-02	2008-11-13	Portola Pharmaceuticals, Inc.	Combination therapy with a compound acting as a platelet adp receptor inhibitor
WO2008141119A2 (en)	2007-05-09	2008-11-20	Vertex Pharmaceuticals Incorporated	Modulators of cftr
AU2008256717B2 (en) *	2007-05-25	2013-11-21	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20110177999A1 (en) *	2007-08-09	2011-07-21	Vertex Pharmaceuticals Incorporated	Therapeutic Combinations Useful in Treating CFTR Related Diseases
CN101827593B (zh)	2007-08-24	2013-07-24	沃泰克斯药物股份有限公司	用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
DE102007042754A1 (de)	2007-09-07	2009-03-12	Bayer Healthcare Ag	Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
MX2010002974A (es)	2007-09-14	2010-07-29	Vertex Pharma	Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
NZ583878A (en) *	2007-09-14	2012-10-26	Vertex Pharma	Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
FR2921657A1 (fr)	2007-09-28	2009-04-03	Sanofi Aventis Sa	Derives de nicotinamide, leur preparation et leur application en therapeutique
EP2578571B1 (en) *	2007-11-16	2015-09-16	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-binding cassette transporters
DE102007058718A1 (de)	2007-12-06	2009-06-10	Erweka Gmbh	Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
ES2625957T3 (es)	2007-12-07	2017-07-21	Vertex Pharmaceuticals Incorporated	Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
LT3170818T (lt)	2007-12-07	2020-05-25	Vertex Pharmaceuticals Incorporated	Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
MX2010006238A (es)	2007-12-07	2010-08-11	Vertex Pharma	Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
JP5637859B2 (ja)	2007-12-13	2014-12-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
NZ720282A (en) *	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
US8343774B2 (en)	2008-02-29	2013-01-01	Waters Technologies Corporation	Chromatography-based monitoring and control of multiple process streams
NZ616097A (en)	2008-03-31	2015-04-24	Vertex Pharma	Pyridyl derivatives as cftr modulators
GB0813709D0 (en)	2008-07-26	2008-09-03	Univ Dundee	Method and product
US20100256184A1 (en)	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
EP3345625B1 (en)	2008-08-13	2020-12-09	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
KR20110063578A (ko)	2008-09-29	2011-06-10	버텍스 파마슈티칼스 인코포레이티드	3－（6－（1－（2,2－디플루오로벤조［ｄ］［1,3］디옥솔－5－일）사이클로프로판카복스아미도）－3－메틸피리딘－2－일）벤조산의 투여 단위
ES2483690T3 (es)	2008-10-23	2014-08-07	Vertex Pharmaceuticals Incorporated	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2010048573A1 (en) *	2008-10-23	2010-04-29	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US20110257223A1 (en)	2008-10-23	2011-10-20	Vertex Pharmaceuticals Incorporated	Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
US8314239B2 (en)	2008-10-23	2012-11-20	Vertex Pharmaceutical Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN102203588B (zh)	2008-10-31	2015-03-18	生物梅里埃公司	利用光谱分离,表征和/或标识微生物的方法
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
PL2365972T3 (pl)	2008-11-06	2015-05-29	Vertex Pharma	Modulatory transporterów posiadających kasetę wiążącą ATP
WO2010078103A1 (en) *	2008-12-30	2010-07-08	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN102361856A (zh)	2009-03-20	2012-02-22	沃泰克斯药物股份有限公司	囊性纤维化跨膜传导调节因子的调节剂
KR101955863B1 (ko) *	2009-03-20	2019-03-07	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
DK2427166T3 (da)	2009-05-07	2014-01-27	Gea Pharma Systems Ltd	Tabletfremstillingsmodul og fremgangsmåde til kontinuerlig fremstilling af tabletter
MX2012003343A (es) *	2009-09-17	2012-08-17	Vertex Pharma	Proceso para preparar compuestos azabiciclicos.
CN102665715A (zh) *	2009-10-22	2012-09-12	沃泰克斯药物股份有限公司	治疗囊性纤维化和其他慢性疾病的组合物
MX2012004790A (es) *	2009-10-23	2013-02-01	Vertex Pharma	Proceso para preparar moduladores del regulador de conductancia transmembrana de fibrosis quistica.
RU2568608C2 (ru) *	2009-10-23	2015-11-20	Вертекс Фармасьютикалз Инкорпорейтед	Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида
WO2011116397A1 (en)	2010-03-19	2011-09-22	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN109081804B (zh)	2010-03-25	2021-12-10	弗特克斯药品有限公司	环丙烷甲酰胺的固体形式
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
TWI549950B (zh)	2010-04-07	2016-09-21	維泰克斯製藥公司	３－（６－（１－（２，２－二氟苯并［ｄ］［１，３］二氧雜環戊烯－５－基）環丙烷甲醯胺基）－３－甲基吡啶－２－基）苯甲酸之固體形式
SI3150198T1 (sl)	2010-04-07	2021-11-30	Vertex Pharmaceuticals Incorporated	Farmacevtski sestavki 3-(6-(1-(2,2-difluorobenzo(D)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline in dajanje le-teh
KR20130056244A (ko)	2010-04-22	2013-05-29	버텍스 파마슈티칼스 인코포레이티드	시클로알킬카르복스아미도-인돌 화합물의 제조 방법
NZ603043A (en)	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
EP3138563A1 (en)	2010-04-22	2017-03-08	Vertex Pharmaceuticals Inc.	Pharmaceutical compositions and administrations thereof
NZ603044A (en)	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
EP2575814A1 (en)	2010-05-20	2013-04-10	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
WO2011146886A1 (en) *	2010-05-20	2011-11-24	Vertex Pharmaceuticals Incorporated	Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
AU2011293658B2 (en)	2010-08-23	2015-03-05	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
NZ607494A (en) *	2010-08-27	2015-04-24	Vertex Pharma	Pharmaceutical composition and administrations thereof
KR101719699B1 (ko) *	2010-10-05	2017-03-27	삼성전자주식회사	메모리 모듈 및 이의 제조 방법
CN102058889A (zh)	2010-11-05	2011-05-18	王定豪	包含抗凝血类药物的分散片及其应用
US8802700B2 (en) *	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
CN102507770A (zh)	2011-10-25	2012-06-20	中国检验检疫科学研究院	检测化妆品中六氯酚的高效液相色谱法
WO2013067410A1 (en)	2011-11-02	2013-05-10	Vertex Pharmaceuticals Incorporated	Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases
US20140127901A1 (en)	2012-11-08	2014-05-08	Taiwan Semiconductor Manufacturing Company, Ltd.	Low-k damage free integration scheme for copper interconnects
AU2012335714B2 (en)	2011-11-08	2017-04-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
ME03464B (me)	2012-01-25	2020-01-20	Vertex Pharma	Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
US8798308B2 (en) *	2012-02-21	2014-08-05	Bose Corporation	Convective airflow using a passive radiator
AU2013226076B2 (en)	2012-02-27	2017-11-16	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en) *	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2013253790A (ja)	2012-06-05	2013-12-19	Chube Univ	ニバレノールの分析法
WO2013185112A1 (en)	2012-06-08	2013-12-12	Vertex Pharmaceuticals Incorporated	Pharmaceuticl compositions for the treatment of cftr -mediated disorders
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2879554A1 (en) *	2012-08-06	2014-02-13	Senomyx, Inc.	Substituted 4-amino-1h-2,1,3-benzothiadiazine 2,2-dioxide compounds and their use as sweet flavor modifiers
US20140092376A1 (en)	2012-10-01	2014-04-03	Momentive Performance Materials, Inc.	Container and method for in-line analysis of protein compositions
RS57831B2 (sr) *	2012-11-02	2024-02-29	Vertex Pharma	Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr
US9636301B2 (en)	2012-12-04	2017-05-02	Arbutus Biopharma Corporation	In vitro release assay for liposome encapsulated vincristine
US20140221424A1 (en) *	2013-01-30	2014-08-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for use in the treatment of cystic fibrosis
CN103743826B (zh)	2013-08-28	2015-12-02	合肥久诺医药科技有限公司	一种阿齐沙坦的高效液相色谱分析方法
CN103822976B (zh)	2013-10-15	2015-05-27	辽宁省食品药品检验所	一种测定化妆品中4-甲氧基水杨酸钾的方法
RS61790B1 (sr)	2013-11-12	2021-06-30	Vertex Pharma	Proces pripreme farmaceutskih sastava za lečenje bolesti na koje utiče cftr
HUE039062T2 (hu)	2014-04-15	2018-12-28	Vertex Pharma	Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
CN104090038B (zh)	2014-07-07	2015-09-30	黄宏南	一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法
CN104122346B (zh)	2014-07-31	2016-03-16	国家烟草质量监督检验中心	一种水基胶中尿素含量的测定方法
CN104122345B (zh)	2014-07-31	2015-08-12	国家烟草质量监督检验中心	烟用纸中1,1,1-三羟甲基丙烷的测定方法
AU2015330923B2 (en)	2014-10-07	2020-03-12	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
WO2016081556A1 (en)	2014-11-18	2016-05-26	Vertex Pharmaceuticals Incorporated	Process of conducting high throughput testing high performance liquid chromatography
WO2016086136A1 (en)	2014-11-26	2016-06-02	Catabasis Pharmaceuticals, Inc.	Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr)	2014-11-26	2017-10-03	Catabasis Pharmaceuticals Inc	Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016087665A2 (en)	2014-12-05	2016-06-09	Centre National De La Recherche Scientifique (Cnrs)	Compounds for treating cystic fibrosis
ES2749097T3 (es)	2015-01-26	2020-03-19	Rigel Pharmaceuticals Inc	Tetrazolonas como bioisósteros de ácido carboxílico
UY36680A (es)	2015-05-19	2016-12-30	Glaxosmithkline Ip Dev Ltd	Amidas heterocíclicas como inhibidores de quinasa
CN105890945A (zh)	2016-04-01	2016-08-24	中国热带农业科学院分析测试中心	超声离心渗液进样快速测定土壤中速效钾的方法
US20180280349A1 (en)	2017-03-28	2018-10-04	Vertex Pharmaceuticals Incorporated	Methods of treating cystic fibrosis in patients with residual function mutations

2006
- 2006-11-08 ES ES16205718T patent/ES2778846T3/es active Active
- 2006-11-08 LT LTEP14163968.2T patent/LT2774925T/lt unknown
- 2006-11-08 EP EP20150602.9A patent/EP3696174A1/en active Pending
- 2006-11-08 KR KR1020137007109A patent/KR20130042034A/ko not_active Application Discontinuation
- 2006-11-08 EP EP10192912.3A patent/EP2395002B1/en active Active
- 2006-11-08 PT PT101915759T patent/PT2404919E/pt unknown
- 2006-11-08 SI SI200631826T patent/SI2395002T1/sl unknown
- 2006-11-08 KR KR1020087013765A patent/KR101331768B1/ko active IP Right Grant
- 2006-11-08 DK DK06837028.7T patent/DK1945632T3/da active
- 2006-11-08 SI SI200631695T patent/SI2404919T1/sl unknown
- 2006-11-08 DK DK14163968.2T patent/DK2774925T3/en active
- 2006-11-08 ES ES06837028.7T patent/ES2439736T3/es active Active
- 2006-11-08 AU AU2006311650A patent/AU2006311650B2/en not_active Expired - Fee Related
- 2006-11-08 EP EP10191575.9A patent/EP2404919B1/en active Active
- 2006-11-08 PL PL10192912T patent/PL2395002T3/pl unknown
- 2006-11-08 RU RU2008122929A patent/RU2463303C3/ru active Protection Beyond IP Right Term
- 2006-11-08 DK DK10192912.3T patent/DK2395002T3/da active
- 2006-11-08 PL PL10191575T patent/PL2404919T3/pl unknown
- 2006-11-08 EP EP14163968.2A patent/EP2774925B1/en active Active
- 2006-11-08 CA CA2627358A patent/CA2627358C/en active Active
- 2006-11-08 NZ NZ567892A patent/NZ567892A/en unknown
- 2006-11-08 ES ES10192912.3T patent/ES2501594T3/es active Active
- 2006-11-08 PT PT68370287T patent/PT1945632E/pt unknown
- 2006-11-08 KR KR1020137007108A patent/KR20130034062A/ko not_active Application Discontinuation
- 2006-11-08 DK DK10191575.9T patent/DK2404919T3/da active
- 2006-11-08 PT PT101929123T patent/PT2395002E/pt unknown
- 2006-11-08 KR KR1020157007929A patent/KR20150041174A/ko active IP Right Grant
- 2006-11-08 PT PT141639682T patent/PT2774925T/pt unknown
- 2006-11-08 ES ES10191575T patent/ES2431388T3/es active Active
- 2006-11-08 HU HUE14163968A patent/HUE032640T2/en unknown
- 2006-11-08 EP EP06837028.7A patent/EP1945632B1/en active Active
- 2006-11-08 CN CN201210278199.5A patent/CN102775396B/zh active Active
- 2006-11-08 KR KR1020167014530A patent/KR20160067985A/ko not_active Application Discontinuation
- 2006-11-08 PL PL06837028T patent/PL1945632T3/pl unknown
- 2006-11-08 JP JP2008540115A patent/JP5317184B2/ja active Active
- 2006-11-08 KR KR1020137032983A patent/KR101561482B1/ko active IP Right Grant
- 2006-11-08 PL PL14163968T patent/PL2774925T3/pl unknown
- 2006-11-08 WO PCT/US2006/043289 patent/WO2007056341A1/en active Application Filing
- 2006-11-08 US US11/594,431 patent/US7741321B2/en active Active
- 2006-11-08 ZA ZA200803887A patent/ZA200803887B/xx unknown
- 2006-11-08 SI SI200632154A patent/SI2774925T1/sl unknown
- 2006-11-08 SI SI200631716T patent/SI1945632T1/sl unknown
- 2006-11-08 EP EP16205718.6A patent/EP3208272B1/en active Active
- 2006-11-08 ES ES14163968.2T patent/ES2619608T3/es active Active
- 2006-11-08 CN CN2006800505211A patent/CN101356170B/zh active Active
2007
- 2007-05-18 US US11/804,726 patent/US7659268B2/en active Active
2008
- 2008-04-29 IL IL191141A patent/IL191141A/en active IP Right Grant
- 2008-05-05 US US12/114,935 patent/US8993600B2/en active Active
- 2008-06-09 NO NO20082674A patent/NO20082674L/no not_active Application Discontinuation
2009
- 2009-04-17 HK HK09103553.4A patent/HK1125366A1/xx unknown
- 2009-12-04 US US12/630,874 patent/US7956052B2/en active Active
2010
- 2010-04-28 US US12/768,894 patent/US7973038B2/en active Active
2011
- 2011-03-23 US US13/069,889 patent/US8324207B2/en active Active
- 2011-05-16 US US13/108,077 patent/US8318733B2/en active Active
2012
- 2012-06-05 RU RU2012123372A patent/RU2608610C2/ru not_active Application Discontinuation
- 2012-08-27 US US13/595,225 patent/US8461156B2/en active Active
- 2012-09-03 JP JP2012193199A patent/JP5666525B2/ja active Active
- 2012-10-31 IL IL222784A patent/IL222784A/en active IP Right Grant
2013
- 2013-04-26 US US13/871,364 patent/US9216969B2/en active Active
- 2013-04-26 US US13/871,349 patent/US20130245010A1/en not_active Abandoned
- 2013-04-26 US US13/871,356 patent/US8741933B2/en active Active
- 2013-05-06 US US13/887,839 patent/US20130245011A1/en not_active Abandoned
- 2013-05-16 HK HK13105753.1A patent/HK1178892A1/xx unknown
2014
- 2014-04-25 JP JP2014091543A patent/JP5941095B2/ja active Active
- 2014-09-15 CY CY20141100743T patent/CY1115750T1/el unknown
2015
- 2015-05-01 JP JP2015094156A patent/JP2015134835A/ja active Pending
- 2015-10-28 US US14/925,804 patent/US20160143898A1/en not_active Abandoned
2016
- 2016-05-13 LT LTPA2016015C patent/LTC2404919I2/lt unknown
- 2016-05-17 HU HUS1600023C patent/HUS1600023I1/hu unknown
- 2016-05-17 LU LU93073C patent/LU93073I2/fr unknown
- 2016-05-17 CY CY2016012C patent/CY2016012I2/el unknown
- 2016-05-18 NL NL300812C patent/NL300812I2/nl unknown
- 2016-06-01 US US15/170,263 patent/US20180282311A9/en not_active Abandoned
- 2016-06-03 US US15/173,325 patent/US20170107206A1/en not_active Abandoned
- 2016-12-21 RU RU2016150386A patent/RU2765714C2/ru active
2017
- 2017-03-22 CY CY20171100364T patent/CY1118768T1/el unknown
2018
- 2018-11-21 US US16/197,732 patent/US10626111B2/en not_active Expired - Lifetime
2020
- 2020-02-13 US US16/789,945 patent/US11084804B2/en active Active
2021
- 2021-06-29 US US17/362,597 patent/US20220153729A1/en active Pending

Also Published As

Publication number	Publication date
CA2627358A1 (en)	2007-05-18
ES2501594T3 (es)	2014-10-02
CA2627358C (en)	2015-10-06
US20130245011A1 (en)	2013-09-19
LT2774925T (lt)	2017-04-10
US20110172229A1 (en)	2011-07-14
RU2012123372A (ru)	2013-12-10
US10626111B2 (en)	2020-04-21
KR20150041174A (ko)	2015-04-15
SI1945632T1 (sl)	2014-03-31
PL1945632T3 (pl)	2014-03-31
EP2395002A1 (en)	2011-12-14
EP2404919A1 (en)	2012-01-11
US11084804B2 (en)	2021-08-10
DK1945632T3 (da)	2013-12-16
EP3208272A1 (en)	2017-08-23
KR20080066086A (ko)	2008-07-15
KR20160067985A (ko)	2016-06-14
KR20130034062A (ko)	2013-04-04
EP1945632B1 (en)	2013-09-18
US20210024505A1 (en)	2021-01-28
CY1115750T1 (el)	2017-01-25
US20160143898A1 (en)	2016-05-26
US7741321B2 (en)	2010-06-22
JP5317184B2 (ja)	2013-10-16
CN102775396A (zh)	2012-11-14
DK2404919T3 (da)	2013-11-04
NO20082674L (no)	2008-08-07
DK2774925T3 (en)	2017-02-27
US8324207B2 (en)	2012-12-04
RU2463303C2 (ru)	2012-10-10
PT2774925T (pt)	2017-04-04
NL300812I2 (el)	2016-09-26
RU2008122929A (ru)	2009-12-20
US20220153729A1 (en)	2022-05-19
IL222784A (en)	2016-06-30
ES2439736T3 (es)	2014-01-24
ES2778846T3 (es)	2020-08-12
US20170107206A1 (en)	2017-04-20
DK2395002T3 (da)	2014-09-08
LU93073I2 (fr)	2016-07-18
ES2619608T3 (es)	2017-06-26
AU2006311650A1 (en)	2007-05-18
US8741933B2 (en)	2014-06-03
CN101356170A (zh)	2009-01-28
LTC2404919I2 (lt)	2017-12-27
US20080113985A1 (en)	2008-05-15
US20170107205A1 (en)	2017-04-20
US20080306062A1 (en)	2008-12-11
HUE032640T2 (en)	2017-10-30
EP3696174A1 (en)	2020-08-19
NZ567892A (en)	2010-12-24
WO2007056341A1 (en)	2007-05-18
US20110312958A1 (en)	2011-12-22
IL191141A (en)	2013-11-28
IL222784A0 (en)	2012-12-31
US7956052B2 (en)	2011-06-07
US7973038B2 (en)	2011-07-05
JP2009514962A (ja)	2009-04-09
ZA200803887B (en)	2009-12-30
PL2774925T3 (pl)	2017-07-31
EP2404919B1 (en)	2013-08-21
SI2774925T1 (sl)	2017-04-26
RU2765714C2 (ru)	2022-02-02
SI2404919T1 (sl)	2013-12-31
US20100210638A1 (en)	2010-08-19
KR101331768B1 (ko)	2013-11-22
US20080019915A1 (en)	2008-01-24
RU2608610C2 (ru)	2017-01-23
CY1118768T1 (el)	2017-07-12
EP3208272B1 (en)	2020-01-08
US20120322798A1 (en)	2012-12-20
KR20130042034A (ko)	2013-04-25
CN102775396B (zh)	2014-10-08
EP2774925A1 (en)	2014-09-10
PT1945632E (pt)	2013-12-24
RU2016150386A3 (el)	2020-02-26
HUS1600023I1 (hu)	2016-06-28
SI2395002T1 (sl)	2014-10-30
US8318733B2 (en)	2012-11-27
US20180282311A9 (en)	2018-10-04
CY2016012I2 (el)	2016-10-05
EP1945632A1 (en)	2008-07-23
JP2015134835A (ja)	2015-07-27
KR20140009566A (ko)	2014-01-22
JP5941095B2 (ja)	2016-06-29
US20190322650A1 (en)	2019-10-24
EP2774925B1 (en)	2016-12-28
US9216969B2 (en)	2015-12-22
AU2006311650B2 (en)	2012-02-23
US7659268B2 (en)	2010-02-09
HK1125366A1 (en)	2009-08-07
ES2431388T3 (es)	2013-11-26
JP2012233011A (ja)	2012-11-29
KR101561482B1 (ko)	2015-10-20
PL2404919T3 (pl)	2014-01-31
IL191141A0 (en)	2008-12-29
US20130237569A1 (en)	2013-09-12
PL2395002T3 (pl)	2015-04-30
HK1178892A1 (en)	2013-09-19
US8461156B2 (en)	2013-06-11
PT2404919E (pt)	2013-10-22
US20130237568A1 (en)	2013-09-12
US20100087435A1 (en)	2010-04-08
RU2016150386A (ru)	2018-06-21
CN101356170B (zh)	2012-09-26
EP2395002B1 (en)	2014-06-18
PT2395002E (pt)	2014-09-16
JP2014139243A (ja)	2014-07-31
RU2463303C3 (ru)	2022-03-01
JP5666525B2 (ja)	2015-02-12
US8993600B2 (en)	2015-03-31
US20130245010A1 (en)	2013-09-19

Publication	Publication Date	Title
CY2016012I2 (el)	2016-10-05	Ετεροκυκλικη ενωση χρησιμη ως διαμορφωτης μεταφορεων κασετας συνδεσης με ατρ
LTPA2020501I1 (lt)	2020-02-10	Pakeistieji enaminokarbonilo junginiai
DK1919907T3 (da)	2011-04-18	Heterocyklisk forbindelse
BRPI0718509A2 (pt)	2015-09-29	compostos orgânicos heterocíclicos
EP2003132A4 (en)	2010-05-12	HETERO COMPOUND
CY2015026I1 (el)	2017-04-05	Διαμορφωτες μεταφορεων κασετας συνδεσης με ατρ
DK1937650T3 (da)	2011-10-03	Heterocykliske forbindelser
DK1848694T3 (da)	2010-01-25	Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
EP2077267A4 (en)	2010-04-07	CONDENSED HETEROCYCLIC COMPOUND
DK2078010T3 (da)	2014-04-28	Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
NO20084803L (no)	2008-11-19	organiske forbindelser
BRPI0718478A2 (pt)	2013-11-26	Compostos orgânicos
NL1031385A1 (nl)	2006-09-20	Gesubstitueerde sulfonylaminoarylmethylcyclopropaancarbonamideverbindingen.
ATE546440T1 (de)	2012-03-15	Organische verbindungen
EP2269990A4 (en)	2012-04-18	Heterocyclic compound
BRPI0811280A2 (pt)	2015-01-20	Compostos amino-heterocíclicos
EP2079466A4 (en)	2011-09-07	SUBSTITUTED INDOLE COMPOUNDS
ATE443056T1 (de)	2009-10-15	Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
ATE526324T1 (de)	2011-10-15	Substituierte imidazolverbindungen als ksp- inhibitoren
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
BRPI0712902A2 (pt)	2018-10-30	compostos orgânicos
EP2210876A4 (en)	2012-02-01	HETEROCYCLIC CONNECTION
SMT201600119B (it)	2016-07-01	Composto eterociclico aromatico contenente azoto
DK1954668T3 (da)	2012-01-23	Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer
EP2295406A4 (en)	2012-04-18	HETEROCYCLIC CONNECTION